The profound impact of COVID-19 on the control and care of diabetic patients: a comprehensive retrospective cohort study.

Publication date: Dec 21, 2024

The COVID-19 pandemic has led to a significant shift in healthcare services, focusing on pandemic response and emergency preparedness. The Oman Ministry of Health implemented various measures to combat and control COVID-19. However, this shift disrupted routine outpatient appointments, particularly for chronic diseases such as diabetes mellitus (DM) and hypertension (HTN). This study aims to assess the pandemic’s effect on diabetes control, by examining glycated haemoglobin (HbA1c), blood pressure (BP), lipid values (particularly low-density lipoprotein (LDL), body weight/ body mass index (BMI), and comparing these measures to pre-pandemic levels. A retrospective cohort study of 223 people with diabetes (PwD), aged 20-95 years who underwent a blood workup in 2019 and 2020 and were registered in Al-Khuwair Health Centre from March to December 2020. Data was extracted from the Al Shifa 3plus System and National Diabetic Register (NDR), and analyzed using SPSS. Out of 260 PwD identified, 223 met the inclusion criteria, while 37 were excluded due to recent diagnoses or missing follow-up in 2019. Significant changes were observed in HbA1C, systolic blood pressure (SBP), and BMI from 2019 to 2020. Mean HbA1c increased from 6. 9% in 2019 to 7. 2% in 2020. Mean SBP rose from 131. 22 mmHg in 2019 to 134. 84 mmHg in 2020, while mean BMI increased from 30. 49 to 30. 80. No significant changes were found in LDL levels or diastolic BP. The COVID-19 pandemic disrupted healthcare systems globally, and the consequences on health and mortality were not only due to the direct impact of the virus, but also to the modifications in priorities. These interruptions in inconsistent care, had consequences for non-communicable diseases (NCDs) like diabetes. Future strategic plans should be prepared and implemented to manage NCD cases in case of pandemics.

Open Access PDF

Concepts Keywords
95years Adult
Diabetes Aged
Pandemic Aged, 80 and over
Therapy Blood Pressure
Body Mass Index
COVID-19
COVID-19
Diabetes
Diabetes Mellitus
Female
Glycated Hemoglobin
Glycated Hemoglobin
Humans
Hypertension
Male
Middle Aged
Oman
Oman
Pandemics
Primary care
Retrospective Studies
SARS-CoV-2
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergency
disease MESH chronic diseases
disease MESH diabetes mellitus
disease MESH hypertension
disease IDO blood
drug DRUGBANK Methionine
disease MESH non-communicable diseases
pathway REACTOME Reproduction
disease MESH cancer
disease MESH asthma
pathway KEGG Asthma
disease MESH kidney diseases
disease MESH premature death
disease MESH diabetes related complications
disease MESH infection
disease MESH respiratory diseases
disease MESH cytokine storms
disease MESH insulin sensitivity
disease MESH inflammation
drug DRUGBANK Cholesterol
disease MESH metabolic syndrome
disease MESH underweight
disease MESH overweight
disease MESH complications
drug DRUGBANK Coenzyme M
pathway REACTOME Glucose metabolism
disease MESH lifestyle
disease MESH nutritional status
disease MESH Obesity
disease MESH anxiety
disease MESH substance use
disease MESH cardiovascular risk factors
drug DRUGBANK Serine
drug DRUGBANK S-Arsonocysteine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine
disease MESH death
drug DRUGBANK Trestolone
drug DRUGBANK Uric Acid
disease IDO host
pathway REACTOME Metabolism
drug DRUGBANK Tenocyclidine
drug DRUGBANK N N-dimethylarginine
disease IDO country

Original Article

(Visited 3 times, 1 visits today)